Pharmaceuticals North America (NAFTA) Industry Guide - Market Summary, Competitive Analysis and Forecast to 2025
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Pharmaceuticals North America (NAFTA) Industry Guide - Market Summary, Competitive Analysis and Forecast to 2025
Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $412.0 billion in 2020.The US was the fastest growing country, with a CAGR of 4.7% over the 2016-20 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $387.0 billion in 2020. This was followed by Canada and Mexico, with a value of $20.2 and $4.8 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $441.0 billion in 2025, followed by Canada and Mexico with expected values of $19.4 and $4.9 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA pharmaceuticals market by value in 2020?
- What will be the size of the NAFTA pharmaceuticals market in 2025?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $412.0 billion in 2020.The US was the fastest growing country, with a CAGR of 4.7% over the 2016-20 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $387.0 billion in 2020. This was followed by Canada and Mexico, with a value of $20.2 and $4.8 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $441.0 billion in 2025, followed by Canada and Mexico with expected values of $19.4 and $4.9 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA pharmaceuticals market by value in 2020?
- What will be the size of the NAFTA pharmaceuticals market in 2025?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
TABLE OF CONTENTS
Table of Contents
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Pharmaceuticals in Mexico
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 Pharmaceuticals in The United States
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Company Profiles
6.1. Johnson & Johnson
6.2. Pfizer Inc.
6.3. Apotex, Inc.
6.4. Merck & Co., Inc.
6.5. Sanofi SA
6.6. Genomma Lab Internacional SAB de CV
6.7. AstraZeneca PLC
7 Appendix
7.1. Methodology
7.2. About MarketLine
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-25
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-20
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2020-25
Table 4: Canada pharmaceuticals market value: $ billion, 2016-20
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2020
Table 6: Canada pharmaceuticals market share: % share, by value, 2020
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2020-25
Table 8: Canada size of population (million), 2016-20
Table 9: Canada gdp (constant 2005 prices, $ billion), 2016-20
Table 10: Canada gdp (current prices, $ billion), 2016-20
Table 11: Canada inflation, 2016-20
Table 12: Canada consumer price index (absolute), 2016-20
Table 13: Canada exchange rate, 2016-20
Table 14: Mexico pharmaceuticals market value: $ billion, 2016-20
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2020
Table 16: Mexico pharmaceuticals market share: % share, by value, 2020
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2020-25
Table 18: Mexico size of population (million), 2016-20
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2016-20
Table 20: Mexico gdp (current prices, $ billion), 2016-20
Table 21: Mexico inflation, 2016-20
Table 22: Mexico consumer price index (absolute), 2016-20
Table 23: Mexico exchange rate, 2016-20
Table 24: United States pharmaceuticals market value: $ billion, 2016-20
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2020
Table 26: United States pharmaceuticals market share: % share, by value, 2020
Table 27: United States pharmaceuticals market value forecast: $ billion, 2020-25
Table 28: United States size of population (million), 2016-20
Table 29: United States gdp (constant 2005 prices, $ billion), 2016-20
Table 30: United States gdp (current prices, $ billion), 2016-20
Table 31: United States inflation, 2016-20
Table 32: United States consumer price index (absolute), 2016-20
Table 33: United States exchange rate, 2016-20
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: Annual Financial Ratios
Table 36: Johnson & Johnson: Key Employees
Table 37: Johnson & Johnson: Key Employees Continued
Table 38: Pfizer Inc.: key facts
Table 39: Pfizer Inc.: Annual Financial Ratios
Table 40: Pfizer Inc.: Key Employees
Table 41: Pfizer Inc.: Key Employees Continued
Table 42: Apotex, Inc.: key facts
Table 43: Apotex, Inc.: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Sanofi SA: key facts
Table 49: Sanofi SA: Annual Financial Ratios
Table 50: Sanofi SA: Key Employees
Table 51: Sanofi SA: Key Employees Continued
Table 52: Genomma Lab Internacional SAB de CV: key facts
Table 53: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 54: Genomma Lab Internacional SAB de CV: Key Employees
Table 55: AstraZeneca PLC: key facts
Table 56: AstraZeneca PLC: Annual Financial Ratios
Table 57: AstraZeneca PLC: Key Employees
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-25
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-20
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2020-25
Figure 4: Canada pharmaceuticals market value: $ billion, 2016-20
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 6: Canada pharmaceuticals market share: % share, by value, 2020
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2020-25
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2020
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2020
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2020
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2020
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2020
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2020
Figure 14: Mexico pharmaceuticals market value: $ billion, 2016-20
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2020
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2020-25
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2020
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2020
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2020
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2020
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2020
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2020
Figure 24: United States pharmaceuticals market value: $ billion, 2016-20
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 26: United States pharmaceuticals market share: % share, by value, 2020
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2020-25
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2020
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2020
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2020
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2020
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2020
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2020
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Pharmaceuticals in Mexico
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
5 Pharmaceuticals in The United States
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Company Profiles
6.1. Johnson & Johnson
6.2. Pfizer Inc.
6.3. Apotex, Inc.
6.4. Merck & Co., Inc.
6.5. Sanofi SA
6.6. Genomma Lab Internacional SAB de CV
6.7. AstraZeneca PLC
7 Appendix
7.1. Methodology
7.2. About MarketLine
List Of Tables
List of TablesTable 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-25
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-20
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2020-25
Table 4: Canada pharmaceuticals market value: $ billion, 2016-20
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2020
Table 6: Canada pharmaceuticals market share: % share, by value, 2020
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2020-25
Table 8: Canada size of population (million), 2016-20
Table 9: Canada gdp (constant 2005 prices, $ billion), 2016-20
Table 10: Canada gdp (current prices, $ billion), 2016-20
Table 11: Canada inflation, 2016-20
Table 12: Canada consumer price index (absolute), 2016-20
Table 13: Canada exchange rate, 2016-20
Table 14: Mexico pharmaceuticals market value: $ billion, 2016-20
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2020
Table 16: Mexico pharmaceuticals market share: % share, by value, 2020
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2020-25
Table 18: Mexico size of population (million), 2016-20
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2016-20
Table 20: Mexico gdp (current prices, $ billion), 2016-20
Table 21: Mexico inflation, 2016-20
Table 22: Mexico consumer price index (absolute), 2016-20
Table 23: Mexico exchange rate, 2016-20
Table 24: United States pharmaceuticals market value: $ billion, 2016-20
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2020
Table 26: United States pharmaceuticals market share: % share, by value, 2020
Table 27: United States pharmaceuticals market value forecast: $ billion, 2020-25
Table 28: United States size of population (million), 2016-20
Table 29: United States gdp (constant 2005 prices, $ billion), 2016-20
Table 30: United States gdp (current prices, $ billion), 2016-20
Table 31: United States inflation, 2016-20
Table 32: United States consumer price index (absolute), 2016-20
Table 33: United States exchange rate, 2016-20
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: Annual Financial Ratios
Table 36: Johnson & Johnson: Key Employees
Table 37: Johnson & Johnson: Key Employees Continued
Table 38: Pfizer Inc.: key facts
Table 39: Pfizer Inc.: Annual Financial Ratios
Table 40: Pfizer Inc.: Key Employees
Table 41: Pfizer Inc.: Key Employees Continued
Table 42: Apotex, Inc.: key facts
Table 43: Apotex, Inc.: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Sanofi SA: key facts
Table 49: Sanofi SA: Annual Financial Ratios
Table 50: Sanofi SA: Key Employees
Table 51: Sanofi SA: Key Employees Continued
Table 52: Genomma Lab Internacional SAB de CV: key facts
Table 53: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 54: Genomma Lab Internacional SAB de CV: Key Employees
Table 55: AstraZeneca PLC: key facts
Table 56: AstraZeneca PLC: Annual Financial Ratios
Table 57: AstraZeneca PLC: Key Employees
List Of Figures
List of FiguresFigure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-25
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2016-20
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2020-25
Figure 4: Canada pharmaceuticals market value: $ billion, 2016-20
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 6: Canada pharmaceuticals market share: % share, by value, 2020
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2020-25
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2020
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2020
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2020
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2020
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2020
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2020
Figure 14: Mexico pharmaceuticals market value: $ billion, 2016-20
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2020
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2020-25
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2020
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2020
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2020
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2020
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2020
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2020
Figure 24: United States pharmaceuticals market value: $ billion, 2016-20
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2020
Figure 26: United States pharmaceuticals market share: % share, by value, 2020
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2020-25
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2020
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2020
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2020
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2020
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2020
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2020
RELATED REPORTS
Valeant Pharmaceuticals Full Year Operating Financial
Valeant Pharmaceuticals 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the
View ReportTeva Pharmaceuticals Full Year Operating Financial
Teva Pharmaceuticals 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the
View ReportNorth America Hematology Flow Cytometry Database
2024 North America Hematology and Flow Cytometry Database: US, Canada, Mexico--Analyzers and Reagents, Supplier Shares, Test Volume and Sales Segment Forecasts This database from provides the 2023 supplier shares,
View ReportNorth America Hematology Market Shares
2023 North America Hematology Market Shares in the US, Canada and Mexico--Competitive Analysis of Leading and Emerging Market Players This new report provides hematology market shares for Canada, Mexico, and
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
